Skip to main content
Signal8

BRAINSTORM CELL THERAPEUTICS INC. (BCLI) Form 8-K — Nov 16, 2026

$BCLIForm 8-KItems 2.02, 9.01Filed Nov 16, 2026, 4:16 PM ET0001104659-26-128336Original filing

BrainStorm Cell Therapeutics (BCLI) reported Q3 2026 results with a net loss of approximately $1.7 million ($0.14 per share), improved from a $2.1 million loss ($0.19 per share) in Q3 2025, as R&D spending fell to $0.5 million from $0.9 million. The company holds only about $0.35 million in cash and restricted cash against $13.2 million in current liabilities, and its forward-looking statements explicitly cite risks around the ability to raise additional capital and continue as a going concern.

Key figures

Eps
-$0.14 (Q3 2026 net loss per share)
Net Income
-$1.7 million (Q3 2026 net loss)
Cash Position
$0.35 million (cash, cash equivalents, and restricted cash as of September 30, 2026)
Q3 2025 eps
-$0.19
Total assets
$0.84 million
Accounts payable
$7.47 million
Q3 2025 net loss
-$2.1 million
Short term loans
$1.875 million
Total liabilities
$13.17 million
Q3 2025 ga expense
$1.15 million
Q3 2025 rd expense
$0.9 million
Q3 2026 ga expense
$1.09 million
Q3 2026 rd expense
$0.5 million
Shares outstanding
14,259,377
Stockholders deficit
-$12.3 million
Nine month 2026 net loss
-$7.7 million

AI analysis

Red flags4 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.